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and if the use of CT technology can
improve the identification of candidates
for rFVII.12
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INTRODUCTION
Intracerebral hemorrhage is by far the most destructive form of stroke1 . Apart from
the management in a specialized stroke or neurological intensive care unit (NICU),
no specific therapies have been shown to consistently improve outcomes after
ICH2. Current Guidelines endorse early aggressive optimization of physiologic
derangements with ventilatory support when indicated, blood pressure control, reversal
of any preexisting coagulopathy, intracranial pressure monitoring for certain cases,
osmotherapy, temperature modulation, seizure prophylaxis, treatment of hyerglycemia,
and nutritional support in the stroke unit or NICU. Ventriculostomy is the cornerstone
of therapy for control of intracranial pressure patients with intraventricular
hemorrhage. 3, 4 Surgical hematoma evacuation does not improve outcome for most
patients, but is a reasonable option for patients with early worsening due to mass effect
due to large cerebellar or lobar hemorrhages. Promising experimental treatments
involve targeting of molecular mechanisms implicated in inflammation, blood product
degradation, and secondary neuronal damage.

NOVEL THERAPIES FOR ICH
Ultra-early hemostatic therapy
Hematoma volume is an important determinant of mortality after ICH and early
hematoma growth which is the increase in hematoma size within 6 hrs of onset, is
consistently associated with poor clinical outcomes and an increased mortality.5-8
Recombinant factor VII (rFVIIa, Novoseven®, Novo Nordisk), a powerful initiator of
hemostasis, was studied in a randomized, double blind, placebo-controlled study, in
which 399 patients with spontaneous ICH received treatment with rFVIIa at doses of
40, 80, or 160 µg/kg within four hours after ICH onset. Use of rFVII was associated
with a 38% reduction in mortality and significantly improved functional outcomes at
90 days despite a five percent increase in the frequency of arterial thromboembolic
adverse events.9 The phase III FAST study compared doses of 80 and 20 µg/kg of rFVIIa
with placebo in an overall trial population of 841 patients. No significant difference
was found in the main outcome measure, which was the proportion of patients with
death or severe disability according to the modified Rankin scale at 90 days (score
of 5 or 6 but the hemostatic effect and side effect profiles were confirmed.10 On the
basis of these results, routine use of rFVIIa as a hemostatic therapy for all patients with
ICH within a four-hour time window cannot be recommended. The lack of effect of
rfVII in ICH, despite its ability to halt hematoma expansion, suggests that additional or
targeted therapy to sub-groups of patients may alter the outcome after ICH. In a FAST
trial sub-group analysis, a potential effect of rFVII was seen in patients <70 years, baseline hematoma volumes of <60ml, baseline IVH <5ml and time from onset <2.5hrs11 .
Future research is needed to address to potential effects of rFVII in this sub-groups
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A potent inhibitor of fibrin-bound and
free thrombin has been used successfully as an alternative for anticoagulation
in patients with heparin-induced thrombocytopenia, acute ischemic stroke, and
vascular occlusive disease. Animal models
have shown that this agent reduces brain
edema within six hours of administration and therefore, may be an effective
therapy for hematoma-induced edema.

Minocycline
A type of tetracycline has been associated
with neuroprotective properties related
to MMP inhibition, antioxidant and antiinflammatory activity. The effects of this
agent have demonstrated in experimental
models of ICH.13-15

Deferoxamine
A potent iron-chelating compound
promotes excretion of iron when administered orally or intravenously. Based on
the toxicity of iron and oxidative stress
related to hematoma, deferoxamine
was shown to reduce ICH mediated
peri-lesional brain injury in rats16 and
piglets17 injected with autologous blood
into the basal ganglia.

Statins
Rosuvastatin, a potent statin used for
reduction of cardiovascular risk was used
in a small study of ICH patients providing
modest benefits.18

Free radical scavenger (NXY-59)
In a recent clinical trial, the effects of
NXY-59, a free radical scavenger, were
investigated in 607 patients with ICH.
NXY-59 was associated with slightly less
hematoma growth than placebo at 72
hrs after treatment but without effect on
mortality or functional outcomes at 3
months.19 Pioglitazone
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Pioglitazone
A thiazolidinedione is currently approved
for the management of type II diabetes
mellitus and found to modulate peroxisome proliferator-activated receptor
gamma agonists in microglia and macrophages, has demonstrated the ability to
increase hematoma reabsorption and
neuronal protection in animal models. 20 A
phase II clinical trial is currently underway
to test the hypothesis that pioglitazone
is safe and tolerable after ICH. 21 Additional human trials with deferoxamine, 22
statins23 are currently underway.

Temperature modulation (TTM)
Temperature control could potentially
offer benefits related to metabolic
control, ICP control, and inhibition of
the inflammatory cascade, which is
associated with apoptosis and neuronal
death24,25. Hyperthermia is considered to
have detrimental effects to the injured
brain and may well be an initial response
to the initial ictus 26 Several studies have
shown the direct association between
hyperthermia and poor outcomes after
all types of brain injury. 26-28 Szczudlik
et al 29 showed that ICH patients with
onset of hyperthermia on the first day
of hospitalization have greater mortality
and worse functional status 30-days
after the ictus. Sustained fever has been
shown to be independently associated
with poor outcome after ICH. 29 A large
body of experimental evidence indicates
that even small degrees of hyperthermia
can worsen ischemic brain injury by
exacerbating excitotoxic neurotransmitter release, proteolysis, free radical
and cytokine production, blood-brain
barrier compromise, and apoptosis 30,
31
. Brain temperature elevations have
also been associated with hyperemia,
exacerbation of cerebral edema, and
elevated intracranial pressure. 32,33 Recent
experimental data from animal models
of ICH that used bacterial collagenase
infusions, suggested that temperature
modulation improved recovery and
lessened neuronal injury when hypothermia was initiated after 12-hours of
onset34 but this effect was not seen in a
different animal model of “whole blood”
infusion.35 A recent study of ICH patients
suggested that mild induced hypothermia
was associated with less cerebral edema
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without change in hematoma growth or
functional outcome when hypothermia
was started after 6-hours of onset. 36
The American Heart Association (AHA)
has recommended normothermia in the
setting of acute ICH. 37 No method to
accomplish this has been evaluated in a
prospective fashion. Although acetaminophen and cooling blankets are generally
used, efficacy in the intensive care setting
has been questioned.38

Craniotomy and clot evacuation
Craniotomy has been the most studied
intervention for the surgical management
of ICH. Two earlier smaller trials showed
that for patients presenting with moderate
alterations in the state of consciousness,
surgery reduced the risk of death without
improving the functional outcome39 and
that ultra-early evacuation of hematoma
improved the 3-month NIHSS40 without
an effect in mortality but a meta-analysis
of all prior trials of surgical intervention
for supratentorial ICH showed no significant benefit from this intervention.41 The
STICH study, a landmark trial of over
1000 ICH patients, showed that emergent
surgical hematoma evacuation by craniotomy within 72 hours of onset fails to
improve outcome compared to a policy of
initial medical management.42 In a posthoc analysis of STICH, the sub-group
of patients with superficial hematomas
and no IVH had better outcomes in the
surgical arm.43 This observation provided
support for the STICH-II trial, which is
currently enrolling patients. In contrast to
supratentorial ICH, there is much better
evidence that cerebellar hemorrhages
exceeding 3 cm in diameter benefit from
emergent surgical evacuation as abrupt
and dramatic deterioration to coma can
occur within the first 24 hours of onset
in these patients.44 For this reason, it is
generally unwise to defer surgery in these
patients until further clinical deterioration
occurs.

Emergency hemicraniectomy
Hemicraniectomy with duraplasty has
been proposed as a life-saving intervention for several neurological catastrophes
such as malignant MCA infarction and
poor grade SAH. No randomized
controlled trial has been conducted in
patients with ICH. In a recent report of

12 consecutive patients with hypertensive
ICH and treated with hemicraniectomy,
92% survived at discharge and 55% had a
good functional outcome at discharge.45
This preliminary data supports the need
for better-controlled studies addressing
the role of this surgical technique in ICH
patients.

Minimally invasive surgery (MIS)
The advantages of MIS over conventional
craniotomy include reduced operative
time, the possibility of performance
under local anesthesia, and reduced
surgical trauma. Endoscopic aspiration of
supratentorial ICH was studied in a small
single-center randomized controlled
trial.46 The study showed that this technique provided a reduction of mortality
at 6 months in the surgical group but
surgery was more effective in superficial
hematomas and in younger patients (<60
years).46 Similarly, a recent report from
China evaluated the effects of minimally
invasive craniopuncture versus medical
therapy in a cohort of 465 patients with
basal ganglia ICH. Improvement in neurological outcome at 14 days and 3-months
was better in the treatment group, though
no differences were seen in long-term
mortality.47

Thrombolysis and clot evacuation
Thrombolytic therapy and surgical
removal of hematomas is another technique that has been studied in a single
center randomized clinical trial.40 Patients
in the surgical group had better outcome
scores than the medically treated group.
Finally, a multi-center randomized control
trial examined the utility of sterotactic
urokinase infusion when administered
within 72hrs to patients with GCS ≥ 5
and hematomas ≥10ml provided significant reduction in hematoma size and
mortality rate at expense of higher rates
of rebleeding but no significant differences in outcomes measures was seen.48

Thrombolysis after IVH
Intraventricular administration of the
plasminogen activator urokinase every
12 hours may reduce hematoma size
and the expected mortality rate at one
month.49 Several small studies have
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reported the successful use of urokinase or tissue plasminogen activator
(t-PA) for the treatment of IVH, with the
goal of accelerating the clearance of
IVH and improving clinical outcome. 50
A Cochrane systemic review published
in 2002 summarized the experience of
several case series providing evidence
of safety but no definitive efficacy.51 The
ongoing Phase III Clear IVH Trial (Clot
Lysis Evaluating Accelerated Resoution of Intra Ventricular Hemorrhage) is
designed to investigate the optimum dose
and frequency of r-tPA administered via
an EVD to safely and effectively treat IVH
and will soon provide some insight on this
issue. When used off-label, a dose of 1
mg of rt-PA every eight hours (followed
by clamping of the EVD for one hour) is
reasonable until clearance of blood from
the third ventricle has been achieved.
Doses of 3 mg or more of t-PA for IVH
thrombolysis have been associated with
an unacceptably high bleeding rate.

CONCLUSION
Recent attempts to discern the pathophysiology of ICH have provided
meaningful information to support
plausible targets for intervention but
evidence based therapies for ICH are
not yet available. Treatment is primarily
supportive and outcomes remain poor.
Despite a long history of devastating
outcomes and high mortality, there is still
optimism that the management of ICH
will change in the future based on new
insights into the acute pathophysiology of
this disease. A better understanding of the
dynamic process of hematoma growth,
importance of inflammation triggered
by coagulation and products of blood
degradation, and the deleterious effects
of fever and inflammation may provide
feasible targets for future interventions.
Additional invasive and non-invasive
treatment strategies are being tested in
clinical trials and results are forthcoming.
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